Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Investigation of Genetic Risk of Atrial Fibrillation

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2006 by Nagoya University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Nagoya University
ClinicalTrials.gov Identifier:
NCT00412438
First received: December 15, 2006
Last updated: NA
Last verified: December 2006
History: No changes posted

December 15, 2006
December 15, 2006
October 2006
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Investigation of Genetic Risk of Atrial Fibrillation
Investigation of Genetic Risk of Atrial Fibrillation

The atrial fibrillation (AF) is the most common cardiac rhythm disturbance that is responsible for substantial morbidity and mortality independent of associated heart disease or other risk factors. Even in the absence of preexisting cardiovascular disease, AF remains significantly associated with excess mortality rates. The current unsatisfactory treatment for AF comes from lack of understanding of the pathophysiology of AF. The purpose of this study is to identify gene polymorphisms that confer susceptibility to atrial fibrillation. Patients with AF(N=500) and healthy volunteer(N=1000) without AF are enrolled in this study. Patients with coronary artery disease, severe valvular heart disease, cardiomyopathy or heart failure were excluded from the study.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Not Provided
Not Provided
Atrial Fibrillation
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1000
Not Provided
Not Provided

Inclusion Criteria:

  • Clinical diagnosis of atrial fibirillation

Exclusion Criteria:

  • coronary artery disease
  • severe valvular heart disease
  • cardiomyopathy
  • heart failure
Both
Not Provided
Yes
Contact: Kenji Yasui, MD, PhD +81-52-788-6211 kenji@riem.nagoya-u.ac.jp
Contact: Masaki Yamauchi, MD +81-52-788-6210 g030744d@mbox.nagoya-u.ac.jp
Japan
 
NCT00412438
RIEM-G-1
Not Provided
Not Provided
Nagoya University
Not Provided
Study Chair: Kenji Yasui, MD, Phd Department of Bio-information Analysis, Research Institute of Enviromental Medicine, Nagoya University
Nagoya University
December 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP